Functional role of somatostatin receptors in neuroendocrine and immune cells

Annals of Medicine

Volumn 31, Issue SUPPL. 2, 1999, Pages 23-27

  Hofland, Leo J ^a,b   Van Hagen, P Martin ^a   Lamberts, Steven W J ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Immune cell; Mechanism; Neuroendocrine cell; Somatostatin receptor

Indexed keywords

GROWTH HORMONE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

CELL PROLIFERATION; CELL SECRETION; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPOPHYSIS CELL; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; LYMPHOID CELL; NEUROENDOCRINE SYSTEM; NEUROSECRETORY CELL; PRIORITY JOURNAL;

ANIMALS; GROWTH HORMONE; HUMANS; LYMPHOCYTES; NEUROSECRETORY SYSTEMS; RATS; RECEPTORS, SOMATOSTATIN;

EID: 0032747274     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Guillemin R, Gerich JE. Somatostatin: physiological and clinical significance. Annu Rev Med 1976; 27: 379-88.
2. Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334: 246-54.
3. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991; 12: 450-82.
4. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family. Life Sci 1995; 57: 1249-65.
5. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995; 16: 427-42.
6. Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995; 16: 86-8.
7. Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997; 20: 348-67.
8. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen D-M, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998; 282: 737-9.
9. Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr1-5). Endocrinology 1994; 135: 2814-7.
10. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 1997; 99: 789-98.
11. van Hagen PM, Krenning EP, Kwekkeboom DJ, Reubi JC, Anker-Lugtenburg PJ, Lowenberg B, et al. Somatostatin and the immune and haematopoietic system: a review. Eur J Clin Invest 1994; 24: 91-9.
12. Reubi JC, Horisberger, U, Waser B, Gebbers JO, Laissue J. Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology 1992; 103: 1207-14.
13. Reubi JC, Waser B, Horisberger U, Krenning E, Lamberts SWJ, Gebbers J-O, et al. In vitro and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood 1993; 82: 2143-51.
14. Reubi JC, Horisberger U, Kappeler A, Laissue JA. Localization of receptors for vasoactive intestinal peptide, somatostatin and substance P in distinct compartment of human lymphoid organs. Blood 1998; 92: 191-7.
15. Reubi JC, Kappeler A, Waser B, Schonbrunn A, Laissue J. Immunohistochemical localization of somatostatin receptors sst2A in human pancreatic islets. J Clin Endocrinol Metab 1998; 83: 3746-9.
16. Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells. Diabetes 1999; 48: 77-85.
17. Reubi JC, Kappeler A, Waser B, Laissue J, Hipkin RW, Schonbrunn A. Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol 1998; 153: 233-45.
18. 2A in human somatostatin receptor positive tumors. J Clin Endocrinol Metab 1999; 84: 775-80.
19. Panetta R, Patel YC. Expression of mRNA for all 5 human somatostatin receptors (hsstr1-5) in pituitary tumors. Life Sci 1994; 56: 333-42.
20. Moldovan S, Atiya A, Adrian TE, Kleinman RM, Lloyd K, Olthoff R, et al. Somatostatin inhibits B-cell secretion via a subtype-2 somatostatin receptor in the isolated perfused human pancreas. J Surg Res 1995; 59: 85-90.
21. Reubi JC, Maurer R, von Werder R, Torhorst J, Klijn JG, Lamberts SWJ. Somatostatin receptors in human endocrine tumors. Cancer Res 1987; 47: 551-8.
22. Reubi JC, Krenning E, Lamberts SWJ, Kvols L. Somatostatin receptors in malignant tissues. J Steroid Biochem Mol Biol 1990; 37: 1073-7.
23. Hofland LJ, Lamberts SWJ. Somatostatin analogs and receptors: diagnostic and therapeutic applications. In: Arnold A, ed. Endocrine Neoplasms. Norwall, MA: Kluwer Academic Publishers; 1997: 365-82.
24. Hofland LJ, Visser-Wisselaar HA, Lamberts SWJ. Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes. Biochem Pharmacol 1995; 50: 287-97.
25. Schonbrunn A, Gu Y-Z, Dournaud P, Beaudet A, Tannenbaum GS, Brown PJ. Somatostatin receptor subtypes: specific expression and signaling properties. Metabolism 1996; 45 (8 Suppl 1): 8-11.
26. Patel YC, Murthy KK, Escher EE, Banville D, Spiess J, Srikant CB. Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins. Metabolism 1990; 39: 63-9.
27. Viguerie N, Tahiri-Jouti N, Aryal AM, Cambillau C, Scemama JL, Bastie MJ, et al. Direct inhibitory effects of a somatostatin analog, SMS 201-995, on AR4-2J cell proliferation via pertussis toxin-sensitive guanosine triphosphate-binding protein-independent mechanism. Endocrinology 1989; 124: 1017-25.
28. Chou CK, Ho LT, Ting LP, Hu CP, Su TS, Chang WC, et al. Selective suppression of insulin-induced proliferation of cultured human hepatoma cells by somatostatin. J Clin Invest 1987; 79: 175-8.
29. Hofland LJ, van Koetsveld PM, Wouters N, Waaijers M, Reubi J-C, Lamberts SWJ. Dissociation of antiproliferative and antihormonal effects of the somatostatin analogue octreotide on 7315b pituitary tumor cells. Endocrinology 1992; 131: 571-7.
30. Buscail L, Estève J-P, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll A-M, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A 1995; 92: 1580-4.
31. Lopez F, Estève J-P, Buscail L, Delesque N, Saint-Laurent N, Théveniau M, et al. The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signalling. J Biol Chem 1997; 272: 24448-54.
32. Sharma K, Patel YC, Srikant CB. Subtype selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by somatostatin receptor 3. Mol Endocrinol 1996; 10: 1688-96.
33. Sharma K, Srikant CB. Induction of wild-type p53, bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 1998; 76: 259-66.
34. Campbell RM, Scanes CG. Endocrine peptides 'moon-lighting' as immune modulators: roles for somatostatin and GH-releasing factor. J Endocrinol 1995; 147: 383-96.
35. Bathena SJ, Louie J, Schlechter GP, Redman RS, Wahl L, Recant L. Identification of human mononuclear leukocytes bearing receptors for somatostatin and glucagon. Diabetes 1981; 30: 127-31.
36. Hiruma K, Koike T, Nakamura H, Sumida T, Maeda T, Tomioka H, et al. Somatostatin receptors on human lymphocytes and leukaemia cells. Immunology 1990; 71: 480-5.
37. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-31.
38. Tsutsumi A, Takano H, Ichikawa K, Kobayashi S, Koike T. Expression of somatostatin receptor subtype 2 mRNA in human lymphoid cells. Cell Immunol 1997; 181: 44-9.
39. Cardoso A, Ghamrawy GE, Gautron J-P, Horvat B, Gautier N, Enjalbert A, et al. Somatostatin increases mitogen-induced IL-2 secretion and proliferation of human Jurkatt T cells via sst3 receptor isotype. J Cell Biochem 1998; 68: 62-73.
40. Casnici C, Lattuada D, Perego C, Franco P, Marelli O. Inhibitory effect of somatostatin on human T lymphocytes proliferation. Int J Immunopharmacol 1997; 19: 721-7.
41. Sirianni MC, Annibale B, Fais S, Delle Fave G. Inhibitory effect of somatostatin-14 and some analogues on human natural killer cell activity. Peptides 1994; 15: 1033-6.
42. Levite M, Cahalon L, Hershkovic R, Steinman L, Lider O. Neuropeptides, via specific receptors, regulate T cell adhesion to fibronectin. J Immunol 1998; 160: 993-1000.
43. Scolnik MP, Palacios MF, Intebi AD, Diez RA. Octreotide inhibits in vitro B cell differentiation to plasma cells induced by PWM. Int J Immunopathol Pharmacol 1996; 9: 119-22.
44. Kimata H, Yoshida A, Fujimoto M, Mikawa H. Effect of vasoactive intestinal peptide, somatostatin, and substance P on spontaneous IgE and IgG4 production in atopic patients. J Immunol 1993; 150: 4630-40.
45. Peluso G, Petillo O, Melone MAB, Mazzarella G, Ranieri M Tajana GF. Modulation of cytokine production in activated human monocytes by somatostatin. Neuropeptides 1996; 30: 443-51.
46. Jenkins SA, Baxter JN, Day DW, Al-Sumidaie AM, Leinster SJ, Shileds R. The effect of somatostatin and SMS 201-995 on experimentally-induced pancreatitis and endotoxaemia in rats and on monocyte activity in patients with cirrhosis and portal hypertension. Klin Wochenschr 1986; 64: 100-6.
47. Perachi M, Bamonti-Catena F, Bareggi B. Effect of high doses of somatostatin on adenylate cyclase activity in peripheral mononuclear leukocytes from normal subjects and from acute leukemia patients. Experientia 1988; 44: 613-5.
48. Becknet SK, Farrar WL. Potentiation of lymphokine-activated killer cell differentiation and lymphocyte proliferation by stimulation of protein kinase C or inhibition of adenylyl cyclase. J Immunol 1988; 140: 208-14.